These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26457446)

  • 1. Bioresorbable Vascular Scaffolds--Will Promise Become Reality?
    Byrne RA
    N Engl J Med; 2015 Nov; 373(20):1969-71. PubMed ID: 26457446
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioresorbable Scaffolds for Coronary Artery Disease.
    Nathan A; Kobayashi T; Kolansky DM; Wilensky RL; Giri J
    Curr Cardiol Rep; 2017 Jan; 19(1):5. PubMed ID: 28108898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
    Ellis SG; Kereiakes DJ; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; McGreevy R; Zhang Z; Simonton C; Stone GW;
    N Engl J Med; 2015 Nov; 373(20):1905-15. PubMed ID: 26457558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresorbable Scaffold　- Taking the Edge Off?
    Tanaka A
    Circ J; 2016 Apr; 80(5):1100-1. PubMed ID: 27026259
    [No Abstract]   [Full Text] [Related]  

  • 5. The ABSORB III Trial: Potential New Concepts for Intracranial Atherosclerosis in the Post-SAMMPRIS Era.
    Aoun RJ; Sattur MG; Panchanathan RS; Bendok BR
    Neurosurgery; 2016 Feb; 78(2):N19-20. PubMed ID: 26779796
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Shah R; Ramos-Bondy B; Mizeracki A
    Lancet; 2016 May; 387(10031):1903. PubMed ID: 27203646
    [No Abstract]   [Full Text] [Related]  

  • 7. Complex coronary artery bifurcation treatment utilizing everolimus-eluting bioresorbable vascular scaffolds and optical coherence tomography.
    Chan W; Shah A; Džavík V; Overgaard CB
    Coron Artery Dis; 2014 Nov; 25(7):629-31. PubMed ID: 25248139
    [No Abstract]   [Full Text] [Related]  

  • 8. Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds.
    Lee WC; Chung WJ; Fang HY; Wu CJ
    Int J Cardiol; 2016 Mar; 206():58-60. PubMed ID: 26774833
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
    Cassese S; Kastrati A
    Lancet; 2016 May; 387(10031):1904. PubMed ID: 27203648
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect on death of scaffold thrombosis versus stent thrombosis.
    Lafont A; Mennuni MG
    Lancet; 2016 May; 387(10034):2198. PubMed ID: 27302028
    [No Abstract]   [Full Text] [Related]  

  • 11. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting.
    Sato K; Latib A; Panoulas VF; Naganuma T; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 Aug; 7(8):e103-4. PubMed ID: 25086841
    [No Abstract]   [Full Text] [Related]  

  • 13. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease.
    Collet C; de Winter RJ; Onuma Y; Serruys PW
    Expert Opin Drug Deliv; 2016 Oct; 13(10):1489-99. PubMed ID: 27550021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.
    Kuramitsu S; Kazuno Y; Sonoda S; Domei T; Jinnouchi H; Yamaji K; Soga Y; Shirai S; Ando K; Saito S
    Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):34-40. PubMed ID: 26333375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will ABSORB III change my practice? Everolimus-eluting bioresorbable scaffolds for coronary artery disease.
    Cook S; Nef H; Capodanno D; Tamburino C; Baumbach A
    EuroIntervention; 2016 Aug; 12(6):801-4. PubMed ID: 27542795
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
    Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R
    EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.